Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129846 | 0.90 | ALDH1A1 (0.33) | KDM4EMEN1ALDH1A1KMT2AHDAC3 | |
| SCHEMBL3650940 | 0.88 | CACNA1G (0.32) | ROCK2 | |
| SCHEMBL4135549 | 0.88 | DHODH (0.36) | DHODHROCK2ALDH1A1KMT2AHDAC3 | |
| SCHEMBL4123409 | 0.87 | DHODH (0.34) | DHODHROCK2HDAC3HDAC4HDAC6 | |
| SCHEMBL4118235 | 0.85 | DHODH (0.37) | DHODHROCK2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4138889 | 0.83 | NPC1 (0.34) | DHODHROCK2KDM4EMAPK1 | |
| SCHEMBL3652323 | 0.83 | L3MBTL1 (0.31) | DHODHMEN1ALDH1A1KMT2AHDAC3 | |
| SCHEMBL3653891 | 0.82 | ALDH1A1 (0.36) | ROCK2KDM4EMAPK1ALDH1A1KMT2A | |
| SCHEMBL4137738 | 0.80 | EDNRA (0.37) | MEN1KMT2A | |
| SCHEMBL4125986 | 0.79 | ALDH1A1 (0.40) | DHODHROCK2KDM4EMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | DHODH 1560/4885ROCK2 2658/4885KDM4E 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.